E. coli Nissle ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
97	Ulcerative colitis	2

97. Ulcerative colitis

---

Clinical trials : 2,630 /  Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04969679 (ClinicalTrials.gov)	March 16, 2018	7/7/2021	Additive Effect of Probiotics (Mutaflor®) in Patients With Ulcerative Colitis on 5-ASA Treatment.	A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment.	Ulcerative Colitis	Drug: E. coli Nissle 1917 (Mutaflor®);Drug: Placebo	Kangbuk Samsung Hospital	NULL	Completed	19 Years	N/A	All	134	Phase 4	Korea, Republic of
2	NCT01772615 (ClinicalTrials.gov)	May 2011	17/1/2013	Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle	Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle	Ulcerative Colitis	Drug: Ciprofloxacin;Dietary Supplement: E. coli Nissle	Hvidovre University Hospital	NULL	Completed	18 Years	N/A	Both	100	Phase 4	Denmark